Get the Stockscreener App
30.50
2.83%
0.84
Amphastar Pharmaceuticals Inc stock is traded at $30.50, with a volume of 494.90K.
It is up +2.83% in the last 24 hours and up +42.86% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$29.66
Open:
$29.98
24h Volume:
494.90K
Relative Volume:
0.94
Market Cap:
$1.42B
Revenue:
$722.68M
Net Income/Loss:
$134.71M
P/E Ratio:
11.42
EPS:
2.67
Net Cash Flow:
$109.94M
1W Performance:
+2.25%
1M Performance:
+42.86%
6M Performance:
-2.49%
1Y Performance:
-35.42%
1-Day Range:
$29.98
$30.90
1-Week Range:
$29.42
$30.99
52-Week Range:
$20.39
$53.95
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
30.50 | 1.38B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Upgrade | Needham | Hold → Buy |
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
Connor Clark & Lunn Investment Management Ltd. Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals Enters Strategic Licensing Agreement - MSN
Published on: 2025-08-18 07:29:06 - sundaytimes.kr
Amphastar raised to Buy at Needham on iron sucrose injection approval - MSN
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to Buy at Needham & Company LLC - MarketBeat
Is It Too Late to Sell Amphastar Pharmaceuticals Inc.Weekly Profit Analysis & AI Enhanced Execution Alerts - sundaytimes.kr
Drawdown in Amphastar Pharmaceuticals Inc. May Be Nearing EndJuly 2025 Snapshot & Real-Time Stock Entry Alerts - newsimpact.co.kr
Dextrose Injection Market Size, Share, Emerging Demands, - openPR.com
Amphastar boosts pipeline with exclusive licensing deal from Nanjing Anji - MSN
How does Amphastar Pharmaceuticals Inc. perform in inflationary periods2025 Technical Overview & AI Powered Buy and Sell Recommendations - thegnnews.com
5 Insightful Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Up 12.1%Still a Buy? - MarketBeat
Amphastar and Anji make licence agreement for three new peptides - Yahoo Finance
Amphastar Pharmaceuticals Q2 Earnings Call Highlights: Strong BAQSIMI Sales, Manufacturing Expansion, and Regulatory Progress, but Revenue Decline and Competition Challenges. - AInvest
Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights - TipRanks
Amphastar Pharmaceuticals Gets Upgrade to Buy at Needham on AMP-002 Approval - AInvest
Amphastar Pharmaceuticals Upgraded to Buy by Needham Analyst - AInvest
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - Yahoo Finance
Amphastar Pharmaceuticals Secures FDA Approval for Iron Sucrose Injection, Sets Sights on Major Sales Momentum - AInvest
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum - Benzinga
Amphastar Soars 11% on Intraday Surge: What’s Fueling the Momentum? - AInvest
Amphastar Pharmaceuticals upgraded to Buy by Needham after FDA approval for iron sucrose injection. - AInvest
Amphastar stock gains after licensing deal for three peptide therapies By Investing.com - Investing.com Canada
Amphastar Pharmaceuticals: Strategic Positioning and Robust Pipeline Justify Buy Rating - TipRanks
Needham upgrades Amphastar Pharmaceuticals stock to Buy on iron sucrose approval - Investing.com Canada
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Amphastar licenses three peptide therapies in oncology, ophthalmology deal By Investing.com - Investing.com South Africa
Amphastar licenses three peptide therapies in oncology, ophthalmology deal - Investing.com
Amphastar gets FDA nod for generic iron sucrose injection - MSN
Amphastar Shares Rise Following FDA Approval of Generic Iron Sucrose Injection - MSN
Amphastar Pharmaceuticals, Inc. Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd - MarketScreener
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. - ACCESS Newswire
AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones - Yahoo Finance
Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline - insights.citeline.com
Amphastar Pharmaceuticals Receives FDA Approval for Generic Iron Sucrose Injection - AInvest
FDA Approvals for Iron Sucrose Products by Viatris, Amphastar Pharmaceuticals - AInvest
Amphastar Pharmaceuticals (AMPH) stock surges 10.4% on FDA approval for generic Iron Sucrose Injection treatment for iron deficiency anemia. - AInvest
Why Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today - Yahoo Finance
FDA OKs Generic Iron Sucrose for CKD Anemia - Conexiant
Amphastar Soars 14.36% on FDA Approval: A Game-Changer or Fleeting Rally? - AInvest
Amphastar stock rises after FDA approves generic iron sucrose injection By Investing.com - Investing.com Canada
FDA approves Amphastar’s iron sucrose injection for anemia treatment By Investing.com - Investing.com Nigeria
FDA approves Amphastar’s iron sucrose injection for anemia treatment - Investing.com
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP - ACCESS Newswire
18,358 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by XTX Topco Ltd - MarketBeat
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates - msn.com
Utah Medical Products Reports Q2 Decline - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Pfizer beats in Q2 earnings, reaffirms 2025 outlook [Video] - AOL.com
Technical Models Suggest Amphastar Pharmaceuticals Inc. May Rebound Soon - beatles.ru
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):